327 related articles for article (PubMed ID: 33309272)
1. Identification of antiviral antihistamines for COVID-19 repurposing.
Reznikov LR; Norris MH; Vashisht R; Bluhm AP; Li D; Liao YJ; Brown A; Butte AJ; Ostrov DA
Biochem Biophys Res Commun; 2021 Jan; 538():173-179. PubMed ID: 33309272
[TBL] [Abstract][Full Text] [Related]
2. Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2.
Ge S; Lu J; Hou Y; Lv Y; Wang C; He H
Virology; 2021 Aug; 560():110-115. PubMed ID: 34052578
[TBL] [Abstract][Full Text] [Related]
3. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
4. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
5. Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches.
Watashi K
Biochem Biophys Res Commun; 2021 Jan; 538():137-144. PubMed ID: 33272566
[TBL] [Abstract][Full Text] [Related]
6. Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection
Curreli F; Victor SMB; Ahmed S; Drelich A; Tong X; Tseng CK; Hillyer CD; Debnath AK
mBio; 2020 Dec; 11(6):. PubMed ID: 33310780
[TBL] [Abstract][Full Text] [Related]
7. Long-chain polyphosphates impair SARS-CoV-2 infection and replication.
Ferrucci V; Kong DY; Asadzadeh F; Marrone L; Boccia A; Siciliano R; Criscuolo G; Anastasio C; Quarantelli F; Comegna M; Pisano I; Passariello M; Iacobucci I; Monica RD; Izzo B; Cerino P; Fusco G; Viscardi M; Brandi S; Pierri BM; Borriello G; Tiberio C; Atripaldi L; Bianchi M; Paolella G; Capoluongo E; Castaldo G; Chiariotti L; Monti M; De Lorenzo C; Yun KS; Pascarella S; Cheong JH; Kim HY; Zollo M
Sci Signal; 2021 Jul; 14(690):. PubMed ID: 34230209
[TBL] [Abstract][Full Text] [Related]
8. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.
Lu J; Hou Y; Ge S; Wang X; Wang J; Hu T; Lv Y; He H; Wang C
Life Sci; 2021 Feb; 266():118889. PubMed ID: 33310043
[TBL] [Abstract][Full Text] [Related]
9. Sigma Receptor Ligands Prevent COVID Mortality In Vivo: Implications for Future Therapeutics.
Berkowitz RL; Bluhm AP; Knox GW; McCurdy CR; Ostrov DA; Norris MH
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958703
[TBL] [Abstract][Full Text] [Related]
10. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
11. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
Shahbazi B; Mafakher L; Teimoori-Toolabi L
J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
[TBL] [Abstract][Full Text] [Related]
12. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
13. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
15. A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection.
Chen F; Shi Q; Pei F; Vogt A; Porritt RA; Garcia G; Gomez AC; Cheng MH; Schurdak ME; Liu B; Chan SY; Arumugaswami V; Stern AM; Taylor DL; Arditi M; Bahar I
Mol Syst Biol; 2021 Aug; 17(8):e10239. PubMed ID: 34339582
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2.
Tummino TA; Rezelj VV; Fischer B; Fischer A; O'Meara MJ; Monel B; Vallet T; White KM; Zhang Z; Alon A; Schadt H; O'Donnell HR; Lyu J; Rosales R; McGovern BL; Rathnasinghe R; Jangra S; Schotsaert M; Galarneau JR; Krogan NJ; Urban L; Shokat KM; Kruse AC; García-Sastre A; Schwartz O; Moretti F; Vignuzzi M; Pognan F; Shoichet BK
Science; 2021 Jul; 373(6554):541-547. PubMed ID: 34326236
[TBL] [Abstract][Full Text] [Related]
17. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D
Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
19. Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations.
Lazniewski M; Dermawan D; Hidayat S; Muchtaridi M; Dawson WK; Plewczynski D
Methods; 2022 Jul; 203():498-510. PubMed ID: 35167916
[TBL] [Abstract][Full Text] [Related]
20. 17β-estradiol reduces SARS-CoV-2 infection in vitro.
Lemes RMR; Costa AJ; Bartolomeo CS; Bassani TB; Nishino MS; Pereira GJDS; Smaili SS; Maciel RMB; Braconi CT; da Cruz EF; Ramirez AL; Maricatto JT; Janini LMR; Prado CM; Stilhano RS; Ureshino RP
Physiol Rep; 2021 Jan; 9(2):e14707. PubMed ID: 33463909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
